Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel

Start Date01 Jul 2026

Sponsor / Collaborator

Fysioline Oy

IRCT20220211053992N64

/ RecruitingNot Applicable

In vivo fasted-state bioequivalence study of Diclofenac ER tablets manufactured by Exir Pharmaceutical Co. compared to innovator product

Start Date05 May 2026

Sponsor / Collaborator

Exir Pharmaceutical Co.

CTRI/2025/05/086932

/ Not yet recruitingPhase 2/3IIT

A Comparative Clinical Study To Evaluate The Analgesic Effect Of Polyherbal Formulation Sachet And Diclofenac Sachet In Dantashool W.S.R. To Toothache. - NIL

Start Date01 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Diclofenac

100 Translational Medicine associated with Diclofenac

100 Patents (Medical) associated with Diclofenac

15,929

Literatures (Medical) associated with Diclofenac

01 Dec 2026·BIORESOURCE TECHNOLOGY

Lignocellulose precursor regulated radical/non-radical pathways of diclofenac degradation in Fe/biochar activated percarbonate systems

Article

Author: Pei, Chun ; Xu, Lijie ; Lu, Xuxuan ; Gan, Lu ; Huo, Yudong ; Zhang, Ying ; Zhou, Xinyu

Percarbonate (SPC) an environmentally friendly peroxide has attracted increasing attention. Herein, two iron-carbon composites with distinct structures were synthesized regulated by the carbon precursors of cellulose and lignin, and the performance of SPC activation was compared using diclofenac (DCF) as the probe. The cellulose-derived Fe₃C@Cel showed core-shell appearance and graphitic structure, demonstrating stronger ability of adsorption, retaining iron and electron transfer than the lignin-derived Fe⁰@Ln. The removal efficiency of DCF by both catalysts was comparable to that in corresponding processes activating peroxymonosulfate and H₂O₂. The complete degradation of 0.05 mM DCF could be achieved within 10 min. Compared with Fe⁰@Ln, Fe₃C@Cel exhibited more significant advantages in adapting wide pH range and complex water compositions, reducing reagent dosage, and improving sustainability. The DCF removal rate in Fe₃C@Cel/SPC could still maintain 84.0% after 5 cycles. The non-radical electron transfer mechanism contributed more significantly to DCF degradation in Fe₃C@Cel/SPC, while •OH, O₂^•- and CO₃^•- were the dominant contributors in Fe⁰@Ln/SPC. The lattice oxygen and CO groups contributed to the ROS generation in Fe₃C@Cel/SPC process, while the lattice oxygen and homogeneous activation by Fe²⁺ were the main routes of ROS generation in Fe⁰@Ln/SPC process. The identification of primary degradation intermediates revealed that fewer intermediates were identified in Fe₃C@Cel/SPC, and the toxicity evaluation of the intermediates showed general decrease trends of bioconcentration factor, mutagenicity, developmental toxicity and biological toxicity. The intermediates identified in Fe₃C@Cel/SPC showed lower developmental and biological toxicity. The results may provide insights in developing practical and environmentally friendly advanced water treatment technologies.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Phytochemical-driven angiogenesis and mucosal regeneration in gastric ulcer healing: molecular mechanisms, preclinical evidence, and translational perspectives

Review

Author: Arya, Swati ; Grover, Madhuri ; Sailo, Roselyne Lalchhandami ; Sanduja, Mohit ; Gupta, Tinku

Gastric ulcer remains a significant global gastrointestinal condition characterized by disruption of the gastric mucosal barrier, attributed to oxidative stress, inflammation, Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs (aspirin, indomethacin, diclofenac), and compromised tissue repair. While traditional therapies effectively reduce acid secretion and eliminate H. pylori, they often do not actively promote mucosal regeneration and angiogenesis, both of which are crucial for the complete healing of ulcers and the prevention of recurrence. This review integrates molecular mechanisms, preclinical and clinical evidence, advanced delivery strategies, and future translational perspectives to provide a comprehensive overview of phytochemical-mediated gastric ulcer healing. Recent findings suggest that tissue repair mediated by angiogenesis, which is regulated by vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1α, nitric oxide, prostaglandins, NF-κB, PI3K/Akt, modulated mitogen-activated protein kinase (MAPK), and fibroblast growth factors, plays a pivotal role in the restoration of the gastric mucosa. Phytochemicals, such as polyphenols, flavonoids, terpenoids, alkaloids, and other bioactive compounds derived from plants, have shown considerable gastroprotective and pro-healing effects in experimental models. Compounds like curcumin, quercetin, naringin, asiaticoside (20 mg/kg, in rats), glycyrrhizin, berberine, and sulforaphane enhance VEGF expression, promote microvascular regeneration, stimulate epithelial restitution, and restore redox balance, thus expediting the healing of ulcers. Moreover, innovative drug delivery methods enhance the bioavailability and therapeutic effectiveness of phytochemicals. They may be promising adjunctive therapeutic agents for gastric ulcer healing through their ability to modulate mucosal regeneration. Integration of advanced methods, biomarker-based clinical studies, systems biology, and the potential of emerging precision medicine strategies may accelerate translational applications and improve future gastric ulcer management strategies.

01 Nov 2026·MARINE POLLUTION BULLETIN

Multi-class contaminants of emerging concern in threatened coastal elasmobranchs: Novel evidence of early-life exposure in southeastern Brazil

Article

Author: Agudelo, Mónica Alejandra Herrera ; Hoff, Rodrigo ; Hauser-Davis, Rachel Ann ; Saggioro, Enrico Mendes ; Vianna, Marcelo

Contaminants of emerging concern (CEC), including pharmaceuticals and illicit drugs, are being increasingly reported in aquatic environments, although data for marine elasmobranchs remain scarce. This study investigated the occurrence of CEC in elasmobranchs from southeastern Brazil through the LC-MS/MS screening of the liver and muscle of Spiny butterfly rays (Gymnura altavela, n = 14) and the liver, muscle, and brain of Scalloped hammerhead (Sphyrna lewini, n = 16) and Smooth hammerhead (Sphyrna zygaena, n = 2) sharks. Detectable residues were found in seven individuals overall, occurring only in a subset of samples. Gymnura altavela showed the greatest diversity of compounds, including benzoylecgonine, cocaine, diclofenac, sulfamethoxazole, fipronil, and piroxicam, with liver presenting a broader profile than muscle. This is the first report on fipronil, sulfamethoxazole and piroxicam in elasmobranchs. Only one juvenile male S. lewini showed contamination, consisting of triclosan in muscle, and no residues were detected in S. zygaena. The co-occurrence of cocaine and benzoylecgonine, with higher concentrations of the former (~4 μg kg^-1) compared to the latter (0.5-0.7 μg kg^-1) suggests recent sewage-related exposure. All detections occurred in juveniles, indicating early-life exposure. These findings highlight the occurrence of multiple classes of CEC in coastal elasmobranchs from southeastern Brazil and reinforce the need for continued monitoring to clarify exposure routes, tissue distribution, and potential consequences for the health and conservation of threatened marine predators.

News (Medical) associated with Diclofenac

27 Feb 2026

·www.einpresswire.com

ULTRA ADVANC3 and ULTRA ADVANC3 GOLD may be harmful due to hidden drug ingredients

[2-26-2026] The Food and Drug Administration is advising consumers not to purchase or use ULTRA ADVANC3 sold on www.amazon.com or ULTRA ADVANC3 GOLD sold on www.naturistarex.com . These products are promoted and sold for joint pain on various other websites and possibly in some retail stores. FDA laboratory analysis confirmed that ULTRA ADVANC3 and ULTRA ADVANC3 GOLD contain dexamethasone, diclofenac and methocarbamol not listed on the product labels. Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period or at high doses, they can suppress the adrenal gland. Abrupt discontinuation can cause withdrawal symptoms. Additionally, the undeclared dexamethasone in ULTRA ADVANC3 or ULTRA ADVANC3 GOLD may cause serious side effects when combined with other medications. Consumers taking ULTRA ADVANC3 or ULTRA ADVANC3 GOLD should immediately consult with their health care professional to safely discontinue use of these products. The risks of withdrawal from corticosteroids should be assessed by a health care professional. Only licensed health care professionals can evaluate patients for the risk or existence of adrenal suppression. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration and fatal perforation of the stomach and intestines. This hidden drug ingredient also may interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. Methocarbamol is a muscle relaxant that can cause sedation, dizziness, and low blood pressure. Methocarbamol also can impair mental and physical abilities to perform certain tasks, such as driving a motor vehicle or operating machinery. Health care professionals and consumers should report adverse events or side effects related to the use of these products to FDA’s MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. For more information: Content current as of: 02/26/2026 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

09 Jan 2026

·www.prnewswire.com

No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321

Clinical study update UPPSALA, Sweden, Jan. 9, 2026 /PRNewswire/ -- Synartro is advancing the candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy signals. The study was initiated in August 2025 following approval from the Swedish Medical Products Agency (MPA) and the Swedish Ethical Review Authority. The study has enrolled a total of 35 participants with knee osteoarthritis. All four cohorts were recruited and treated within a four-month period: Cohort 1 (n=7), Cohort 2 (n=8), Cohort 3 (n=8), and Cohort 4 (n=12). Following review by the internal safety review committee (iSRC), the highest dose tested in Cohort 3 was approved for expansion in Cohort 4. Cohorts 1-3 have completed the study in accordance with the protocol. Cohort 4 is ongoing, with follow-up assessments conducted at weeks 4 and 6. Last Patient Last Visit (LPLV) is scheduled for the first week of February 2026. Unblinding of the study is planned for the second week of March 2026, after which analyses of safety, tolerability, and pharmacokinetic (PK) data will be performed. Interim safety and pharmacokinetic observations Interim data generated to date are consistent with preclinical observations. No serious adverse events related to the investigational medicinal product (IMP) have been reported. Observed adverse events are consistent with those commonly associated with intra-articular injections. No allergic reactions or immunological safety signals have been observed to date. These observations are based on data available to date, and the study is ongoing. Mean Cmax values in plasma from Cohorts 1 and 2 indicate very low systemic exposure to diclofenac. Cmax data from Cohorts 3 and 4 are pending. Plasma concentrations of diclofenac-derived by-products have been below the limit of quantification, supporting the intended slow-release characteristics of SYN321. CONTACT: For further information, please contact: Magnus Hurst, CFO & acting CEO. Tel: +46 (0) 760 27 44 27. E-mail: [email protected] This information was brought to you by Cision 21% more press release views with Request a Demo

Clinical Study

07 Jan 2026

·www.businesswire.com

Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart ® from IBSA

RALEIGH, N.C.--(BUSINESS WIRE)--Acertis Pharmaceuticals, a specialty pharmaceutical company focused on delivering differentiated therapies to patients, today announced that it has entered into an exclusive agreement with Swiss pharmaceutical company IBSA Institut Biochimique SA to license the U.S. commercial rights for Licart® (diclofenac epolamine topical system 1.3%), the first and only FDA-approved once-daily topical nonsteroidal anti-inflammatory drug (NSAID) patch for the treatment of acute pain due to minor strains, sprains, and contusions. Licart utilizes patented next-generation patch technology to deliver diclofenac epolamine offering patients a fast onset of action within 1–3 hours and sustained pain relief for up to 24 hours. This innovative design provides convenience with once-a-day dosing, for patients managing acute pain due to minor strains, sprains, and contusions. Strengthening Acertis’ Pain Management Portfolio By licensing Licart, Acertis strengthens its growing portfolio of specialty products in pain management and related therapeutic areas. “We are pleased to license Licart as we continue to execute our strategic plan of building a growth-oriented, specialty pharmaceutical company,” said Richard Pascoe, Chief Executive Officer, Acertis Pharmaceuticals. “Licart’s once-daily dosing and advanced delivery system represent a meaningful improvement in topical NSAID therapy, aligning with Acertis’ mission to provide innovative, patient-centric treatment options.” Continued Patient Support Programs Acertis will support Licart with robust patient assistance initiatives, including copay savings programs, direct-to-patient pharmacy services, and educational resources for healthcare providers. Most commercially insured patients may be eligible to pay as little as $15 per prescription through the Licart Copay Card, while the Licart Direct Program offers the lowest available cash price for patients regardless of insurance coverage. About Licart® Licart (diclofenac epolamine topical system 1.3%) is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. As the only FDA-approved once-daily topical NSAID patch, Licart delivers a widely used and well-established NSAID in a unique topical system that combines two innovative drug delivery technologies for enhanced permeability and sustained pain relief. Additional information is available at www.Licart.com. About Acertis Pharmaceuticals Acertis Pharmaceuticals is a specialty pharmaceutical company dedicated to building a differentiated portfolio of products that address unmet needs in pain management and other therapeutic categories. With a focus on licensing, commercialization, and patient-first solutions, Acertis partners with global innovators to bring meaningful therapies to U.S. patients. The company is headquartered in Raleigh, North Carolina. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrates the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. Use & Important Safety Information INDICATIONS AND USAGE LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. LICART is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. CONTRAINDICATIONS LICART is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. In the setting of coronary artery bypass graft (CABG) surgery. On non-intact or damaged skin resulting from any etiology, including exudative dermatitis, eczema, infected lesions, burns or wounds. WARNINGS AND PRECAUTIONS Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. Heart Failure and Edema : Avoid use of LICART in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of LICART in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. Anaphylactic Reactions : Seek emergency help if an anaphylactic reaction occurs. Exacerbation of Asthma Related to Aspirin Sensitivity : LICART is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity). Serious Skin Reactions : Discontinue LICART at first appearance of skin rash or other signs of hypersensitivity. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) : Discontinue and evaluate clinically. Fetal Toxicity : Limit use of NSAIDs, including LICART, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the fetal ductus arteriosus. Hematologic Toxicity : Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. ADVERSE REACTIONS Most common adverse reactions for LICART are application site pruritus and other application site reactions. To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch References: 1. Licart (diclofenac epolamine) topical system 1.3% [package insert]. Parsippany, NJ: IBSA Pharma; 2020. 2. Coudreuse J-M, et al. Curr Med Res Opin. 2010;26(9):2221-2228. Please visit Licart.com for Full Prescribing Information, including Boxed Warning Once-a-day Patch, All-day Relief PR ACRX- 92225

AcquisitionLicense out/inDrug Approval

100 Deals associated with Diclofenac

External Link

KEGG	Wiki	ATC	Drug Bank
D07816	Diclofenac	M01AB05	DB00586

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Osteoarthritis	United States	Zyla Life Sciences US LLC	22 Aug 2014
Acute Pain	United States	Zyla Life Sciences US LLC	18 Oct 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	Phase 3	United States	Pfizer Inc.	25 Jul 2007
Colic	Phase 3	Italy	Pfizer Inc.	01 Apr 2002
Renal Colic	Phase 3	Italy	Pfizer Inc.	01 Apr 2002
Toothache	Phase 2	United States	Iroko Pharmaceuticals LLC	01 Sep 2009
Glaucoma	Phase 2	-	Pharmacia & Upjohn, Inc.	-
Glaucoma	Phase 2	-	InSite Vision, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTRI/2021/01/030592 (D-ToRCH, ASCO_Breakthrough2023) Manual	Phase 3	Breast Cancer	148	Diclofenac	ecibpqufxu(adwthieizs) = kfhwpcyfyn kxbqzctlcz (xclqmpctmd ) View more	Positive	03 Aug 2023
				placebo	ecibpqufxu(adwthieizs) = itygkccrxi kxbqzctlcz (xclqmpctmd ) View more
CTRI/2021/01/030592 (ASCO2023)	Phase 3	Hand-Foot Syndrome	263	Topical diclofenac gel	frskzeuoca(kopratvzfj) = iegdowmjtg oaewuaunfc (kickankkud ) View more	Positive	31 May 2023
				Placebo gel	frskzeuoca(kopratvzfj) = kbbmshlkgj oaewuaunfc (kickankkud ) View more
UEGW2022	Phase 3	Pancreatitis	40	Diclofenac	nbkzlvbhux(uheeamanwk) = olitjeekfl qbdjoiecve (qfiihjtztt )	Positive	09 Oct 2022
				Buprenorphine	nbkzlvbhux(uheeamanwk) = ggstnrblan qbdjoiecve (qfiihjtztt )
NCT00507026 (CTgov)	Phase 3	Pain, Postoperative	277	Diclofenac (Diclofenac (DIC075V))	eiyryenzlc(iosiglqopl) = vhxptfcqym vpxwasxlna (ilcbatuvvt, 570.90) View more	-	29 Oct 2021
				Ketorolac (Ketorolac)	eiyryenzlc(iosiglqopl) = ckxiyqwnva vpxwasxlna (ilcbatuvvt, 586.21) View more
CTRI/2016/09/007302 (ESMO2020)	Phase 3	Pain \| Head and Neck Neoplasms	128	Diclofenac	gxyjmvwtau(ummkhpuobq) = the rate of any grade renal dysfunction was numerically higher in the diclofenac arm (10.6% versus 4.8%, P=0.326) atzwnpmsel (ffwxztpbqd )	Positive	17 Sep 2020
				Tramadol
NCT02424578 (CTgov)	Phase 2	Pain, Postoperative	30	Diclofenac Capsules low dose (Diclofenac Capsules Low Dose)	glhgwtrihu(smevbpprgq) = qfxrvcdlfv usmvibxsej (rwbaphltsp, 3710.526) View more	-	13 Jul 2017
				Diclofenac Capsules high dose (Diclofenac Capsules High Dose)	glhgwtrihu(smevbpprgq) = znnhpclhjd usmvibxsej (rwbaphltsp, 5660.83) View more
NCT01943435 (CTgov)	Not Applicable	Spinal stenosis of lumbar region	259	Lumbar epidural injection+nortriptyline+acetaminophen+diclofenac+misoprostol+duloxetine+celecoxib+gabapentin+tramadol+sertraline+mirtazapine+ibuprofen+trazodone (Medical Care)	vnbfaqefxa(qkgebgiglh) = eajfopcrhf hocfvytzml (fsnwvuaqtg, 5.5) View more	-	17 May 2017
				Group Exercise: community setting (Group Exercise)	vnbfaqefxa(qkgebgiglh) = nsjczetnlz hocfvytzml (fsnwvuaqtg, 5.2) View more
ACR2014	Not Applicable	Osteoarthritis	-	SoluMatrix diclofenac 35-mg capsules BID	ohllaojajb(pfzydqobpn) = sgclighypw doviczkouz (iywgakknzx ) View more	-	14 Nov 2014
NCT01461369 (Pubmed \| Curr Med Res Opin)	Phase 3	Osteoarthritis	305	Submicron diclofenac 35mg tid	oauxgamsoj(damccvoges) = jiqogmfdpk nxjchgjhan (xtmaiyjseu )	-	01 Sep 2014
				Placebo	oauxgamsoj(damccvoges) = ccewnfyefs nxjchgjhan (xtmaiyjseu )
NCT01510912 (CTgov)	Phase 3	Osteoarthritis	602	Diclofenac	slmeytvbxu = goeuafmjrv zzgcvpjazk (hcvbpgypgi, cajkritwwv - ztrxdqmvpj) View more	-	09 May 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis